Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7666497 | 0.89 | RAB9A (0.53) | KCNMA1GAAMEN1KMT2ANPC1 | |
| SCHEMBL7664623 | 0.83 | KCNMA1 (0.64) | KCNMA1GAAMEN1KMT2ATP53 | |
| SCHEMBL7660103 | 0.83 | TAS1R3 (0.48) | KCNMA1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6991334 | 0.81 | KCNMA1 (0.57) | KCNMA1GAAMEN1KMT2ANPC1 | |
| SCHEMBL6994754 | 0.80 | NPC1 (0.60) | KCNMA1GAAMEN1KMT2ANPC1 | |
| SCHEMBL14363390 | 0.79 | KCNMA1 (0.66) | KCNMA1GAAMEN1KMT2ANPC1 | |
| SCHEMBL4928655 | 0.75 | KCNMA1 (0.70) | KCNMA1GAAMEN1KMT2ANPC1 | |
| SCHEMBL6029542 | 0.74 | KCNMA1 (0.84) | KCNMA1GAAMEN1KMT2ANPC1 | |
| SCHEMBL2605548 | 0.72 | KCNMA1 (0.82) | KCNMA1GAAMEN1KMT2ANPC1 | |
| SCHEMBL4916420 | 0.72 | GAA (0.80) | KCNMA1GAAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455521-B1 | PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020042411-A1 | Condensed thiophene compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6271225-B1 | PSYCHOLOGICAL DISORDERS | WELFIDE CORPORATION (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-1016664-A1 | FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042411-A1 | Condensed thiophene compounds and pharmaceutical use thereof | ACIN1, ACHE, TPMT | KCNMA1 2043/4885GAA 75/4885MEN1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.